RxDoctor Payments Data

Mikel Muse, DO

MOHS-Micrographic Surgery · Vancouver, WANPI 1639639339

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.2% of the total across 167 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,382 and has fallen 58.7% since, to $985 in 2025. Among mohs-micrographic surgery clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,877in general payments, 2019–2025

Across 167 payments — averaging $35.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$756
  • Dermavant Sciences, Inc.$524
  • LEO Pharma Inc.$500
  • UCB, Inc.$448
  • Sanofi$407
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$5,65296%
  • Education$2254%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,877 in reported general payments places this provider in the 90th percentile of 38 mohs-micrographic surgery providers in Washington.

See all mohs-micrographic surgery providers in Washington

Medicare billing

Part B allowed, 2024
$91,430
Medicare patients
400
Services billed
1,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab12$45,441
Fluorouracil83$6,010
Metronidazole17$2,821
Ketoconazole167$2,811
Tretinoin19$1,862
Tacrolimus23$1,663
Clindamycin Phosphate42$1,597
Clobetasol Propionate42$1,224
CiclopiroxCiclopirox Olamine49$1,034
Triamcinolone Acetonide91$900
Doxycycline Monohydrate23$605
Fluocinolone Acetonide15$586
Mupirocin56$406
Ciclopirox11$341
Ammonium Lactate11$336

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Vancouver

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →